US-based health solutions company Maternova has entered into an international distribution agreement with Canadian rapid diagnostics manufacturer MedMira.
Under the terms of the agreement, Maternova will obtain exclusive distribution rights across Latin America, and non-exclusive rights in the US, for MedMira’s Multiplo and Miriad brands.
The Multiplo and Miriad brand products are intended for the treatment of HIV, hepatitis, syphilis, and other infectious and sexually transmitted diseases.
Maternova founder and chief of strategy Meg Wirth said: “Sexually transmitted infections are a growing threat to maternal and infant health.
“MedMira’s Rapid Vertical Flow platform provides tests with immediate results that are highly sensitive and specific, all of the qualities needed by clinicians.
“These tests will be an invaluable resource in a broad range of healthcare settings and a timely addition to Maternova’s targeted distribution channels in Latin America and the United States.”
The new distribution partnership would expand Maternova’s product lines with additional products, including the Multiplo TP/HIV rapid test.
The TP/HIV rapid test is designed to deliver 100% sensitivity in identifying co-infections and help reduce mother-to-child transmission (MTCT) of syphilis and HIV.
In addition, the Reveal G4 HIV rapid test provides superior sensitivity and specificity, according to recent studies conducted by the CDC.
MedMira manufactures all the products exclusively in Canada, in a facility certified by the US Food and Drug Administration (FDA) and Medical Device Single Audit Program (MDSAP).
MedMira CEO Hermes Chan said: “MedMira has developed a number of highly valuable and essential rapid tests to provide immediate quality answers in any setting.
“Our core focus is the development and manufacturing of our technologies and products, and we are delighted to partner with Maternova to access new markets and new customers.
“Maternova’s commercialisation expertise and extensive network in Latin America and the United States offer a highly valued next step in our mutual growth.”
